{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:28:49Z","timestamp":1790674129770,"version":"4.1.0"},"reference-count":56,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hepatitis C virus infection has a substantial effect on morbidity and mortality worldwide because it is a cause of cirrhosis, hepatocellular carcinoma, liver transplantation, and liver-related death. Direct acting antiviral drugs available today have high efficacy and excellent safety and can be used in all patients with clinically evident chronic liver disease and in groups that demonstrate risk behaviors to reduce the spread of infection. The Global Health Strategy of WHO to eliminate hepatitis infection by 2030 assumes \u201ca 90% reduction in new cases of chronic hepatitis C, a 65% reduction in hepatitis C deaths, and treatment of 80% of eligible people with HCV infections\u201d. In this review effective models and strategies for achieving the global elimination of HCV infection are analyzed. The screening strategies must be simple and equally effective in high-risk groups and in the general population; fast and effective models for appropriate diagnosis of liver disease are needed; strategies for direct acting antiviral drug selection must be cost-effective; linkage to care models in populations at risk and in marginalized social classes must be specifically designed and applied; strategies for obtaining an effective vaccine against HCV infection have yet to be developed.<\/jats:p>","DOI":"10.3390\/v14030505","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T20:11:57Z","timestamp":1646079117000},"page":"505","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Hepatitis C: Standard of Treatment and What to Do for Global Elimination"],"prefix":"10.3390","volume":"14","author":[{"given":"Lorenza","family":"Di Marco","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Department of Medical Specialties, University of Modena & Reggio Emilia, 41100 Modena, Italy"},{"name":"Clinical and Experimental Medicine PhD Program, University of Modena & Reggio Emilia, 41100 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6570-889X","authenticated-orcid":false,"given":"Claudia","family":"La Mantia","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Di Marco","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","article-title":"Extrahepatic morbidity and mortality of chronic hepatitis C","volume":"149","author":"Negro","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/jvh.12483","article-title":"Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: An economic model from five European countries","volume":"23","author":"Younossi","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: A meta-analysis of prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_6","unstructured":"The Polaris Observatory HCV Collaborators (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol. Hepatol., 2, 161\u2013176."},{"key":"ref_7","unstructured":"Assembly WHOS-NWH (2016, June 30). Draft Global Health Sector Strategies Viral Hepatitis 2016\u20132021. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf."},{"key":"ref_8","unstructured":"WHO (2016). Combating Hepatitis B and C to Reach Elimination by 2030, World Health Organization."},{"key":"ref_9","unstructured":"Dowdle, W.R., and Hopkins, D.R. (1998). Considerations for Viral Disease Eradication: Lessons Learned and Future Strategies: Workshop Summary, John Wiley & Sons."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/liv.13668","article-title":"Is global elimination of HCV realistic?","volume":"38","author":"Calvaruso","year":"2018","journal-title":"Liver Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/liv.14011","article-title":"Hepatitis C: Is eradication possible?","volume":"39","author":"Lombardi","year":"2019","journal-title":"Liver Int."},{"key":"ref_12","unstructured":"WHO (2016). Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version, World Health Organization."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC Recommendations for Hepatitis C Screening Among Adults\u2014United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100442","DOI":"10.1016\/j.epidem.2021.100442","article-title":"Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression","volume":"34","author":"Kondili","year":"2021","journal-title":"Epidemics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/liv.14408","article-title":"Optimization of hepatitis C virus screening strategies by birth cohort in Italy","volume":"40","author":"Kondili","year":"2020","journal-title":"Liver Int."},{"key":"ref_16","unstructured":"European Union HCV Collaborators (2017). Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: A modelling study. Lancet Gastroenterol. Hepatol., 2, 325\u2013336."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/liv.14796","article-title":"Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements","volume":"41","author":"Kondili","year":"2021","journal-title":"Liver Int."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"AASLD-IDSA HCV Guidance Panel (2018). Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis., 67, 1477\u20131492.","DOI":"10.1093\/cid\/ciy585"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/M16-0065","article-title":"Hepatitis C core antigen testing for diagnosis of hepatitis c virus infection: A systematic review and meta-analysis","volume":"165","author":"Freiman","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1111\/liv.14242","article-title":"Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study)","volume":"39","author":"Calvaruso","year":"2019","journal-title":"Liver Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.2014.12627","article-title":"Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population","volume":"312","author":"Wedemeyer","year":"2014","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"376","author":"Gordon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmaco-kinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): A combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/jvh.12754","article-title":"HBV reactivation in patients with HCV\/HBV cirrhosis on treatment with direct-acting antivirals","volume":"25","author":"Calvaruso","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2018.05.039","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients","volume":"69","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/Pibrentasvir Treatment in Liver or Kidney Transplant Patients with Hepatitis C Virus Infection","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3201\/eid2205.151980","article-title":"Linkage to care for suburban heroin users with hepatitis C virus infection, New Jersey, USA","volume":"22","author":"Akyar","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1370\/afm.2069","article-title":"A Hepatitis C Treatment Program Based in a Safety-Net Hospital Patient-Centered Medical Home","volume":"15","author":"Lasser","year":"2017","journal-title":"Ann. Fam. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/cid\/cit271","article-title":"Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all","volume":"57","author":"Bruggmann","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/M17-1073","article-title":"Curing Hepatitis C Virus Infection: Best Practices from the U.S. Department of Veterans Affairs","volume":"167","author":"Belperio","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_34","first-page":"1084","article-title":"Use of telemedicine technologies in the management of infectious diseases: A review","volume":"60","author":"Parmar","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12889-019-6784-3","article-title":"Hepatitis C prevalence and risk factors in Georgia, 2015: Setting a baseline for elimination","volume":"19","author":"Hagan","year":"2019","journal-title":"BMC Public Health"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chikovani, I., Ompad, D.C., Uchaneishvili, M., Sulaberidze, L., Sikharulidze, K., Hagan, H., and van Devanter, N.L. (2019). On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216123"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jhep.2019.07.006","article-title":"Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting","volume":"71","author":"Dhiman","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_38","first-page":"329","article-title":"Increasing Access to Hepatitis C Virus Medications: A Program Model Using Patient Navigators and Specialty Pharmacy to Obtain Prior Authorization Approval","volume":"24","author":"Vu","year":"2018","journal-title":"J. Manag. Care Sp\u00e9c. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14218\/JCTH.2016.00011","article-title":"Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States","volume":"4","author":"Saab","year":"2016","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2019.10.010","article-title":"Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial","volume":"72","author":"Dore","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1093\/infdis\/jiaa141","article-title":"Development of an Interdisciplinary Telehealth Model of Provider Training and Comprehensive Care for Hepatitis C and Opioid Use Disorder in a High-Burden Region","volume":"222","author":"Sherbuk","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2468-1253(20)30120-5","article-title":"Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: A pragmatic, cluster-randomised trial","volume":"5","author":"Radley","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jhep.2016.09.004","article-title":"HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe","volume":"66","author":"Ingiliz","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jvh.12666","article-title":"HCV reinfection incidence among individuals treated for recent infection","volume":"24","author":"Martinello","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jceh.2018.02.003","article-title":"Hepatitis C Virus Infection and Vaccine Development","volume":"8","author":"Guo","year":"2018","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1053\/j.gastro.2010.05.077","article-title":"Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural Proteins","volume":"139","author":"Dahari","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine","volume":"12","author":"Grebely","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection","volume":"138","author":"Osburn","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/nature04079","article-title":"Adaptive immune responses in acute and chronic hepatitis C virus infection","volume":"436","author":"Bowen","year":"2005","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gutjnl-2011-300620","article-title":"T cell responses in hepatitis C: The good, the bad and the unconventional","volume":"61","author":"Klenerman","year":"2012","journal-title":"Gut"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.3390\/v3112127","article-title":"Neutralizing antibody response to hepatitis C virus","volume":"3","author":"Wang","year":"2011","journal-title":"Viruses"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/hep.27013","article-title":"Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses","volume":"59","author":"Osburn","year":"2014","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0168-8278(99)80375-4","article-title":"Viral heterogeneity of the hepatitis C virus","volume":"31","author":"Simmonds","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1586\/erv.11.55","article-title":"Vaccination for hepatitis C virus: Closing in on an evasive target","volume":"10","author":"Halliday","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-020-00669-4","article-title":"Hepatitis C virus vaccine design: Focus on the humoral immune response","volume":"27","author":"Resino","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3389\/fimmu.2018.01480","article-title":"Hepatitis C Vaccines, Antibodies, and T Cells","volume":"9","author":"Shoukry","year":"2018","journal-title":"Front. Immunol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/3\/505\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:29:45Z","timestamp":1760135385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/3\/505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":56,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["v14030505"],"URL":"https:\/\/doi.org\/10.3390\/v14030505","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}